CJC-1295 DAC Dosage for Weight Loss: What the Research Actually Shows

There is no established CJC-1295 DAC dosage for weight loss, and no regulatory agency has approved CJC-1295 DAC for human use anywhere in the world. The numbers that circulate online come from small pharmacokinetic studies that measured growth hormone and IGF-1 levels, not body fat. No published human trial has tested CJC-1295 DAC as a weight-loss agent or reported fat loss as an outcome.

What CJC-1295 DAC Is

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), the signal the hypothalamus uses to tell the pituitary to release growth hormone. The "DAC" stands for Drug Affinity Complex, a modification that lets the peptide bind to albumin in the bloodstream.

That binding stretches the half-life from minutes to roughly six to eight days. Anyone comparing the cjc-1295 with dac dosage against the cjc-1295 no dac dosage is looking at two very different pharmacokinetic profiles rather than two strengths of the same compound.

CJC-1295 DAC is sold as a research chemical. It is not an approved medication, and it is not a dietary supplement. CJC-1295 DAC is not FDA-approved for human use in the United States.

Is There an Official CJC-1295 DAC Dosage for Weight Loss?

No. There is no approved dose of CJC-1295 DAC for any indication, and there is no research consensus on a weight-loss-specific dose. A few facts explain why:

• Early human studies of CJC-1295 used single or repeated doses in the 30–60 mcg/kg range and tracked hormone levels, not body weight.
• Weight loss was never a primary or secondary endpoint in that research.
• Online protocols citing 1–2 mg per week are extrapolations from half-life data, not tested regimens.
• Research-grade peptides are not standardized, so the actual amount of drug in a vial is frequently unknown.

In practical terms, a validated CJC-1295 DAC dosage for weight loss simply does not exist in the peer-reviewed literature. An absence of data is not the same thing as evidence of safety or effectiveness.

Commonly Cited Doses at a Glance

The table below summarizes figures that appear in research papers and in online discussion. None of them are prescribing guidelines, and none of these compounds are approved for human use.

Why Growth Hormone Peptides Get Tied to Fat Loss

Growth hormone does increase lipolysis, the breakdown of stored fat, and that single fact is the entire basis for the peptide's fat-loss reputation. The effect is real but modest and self-limiting, and it comes with trade-offs.

Sustained GH elevation can raise blood glucose, reduce insulin sensitivity, cause fluid retention and joint pain, and produce tingling in the hands and feet. Those effects are not hypothetical; they appear consistently across GH research.

A compound that raises growth hormone is not automatically a weight-loss drug, and no GHRH analog has ever been approved for that purpose.

Raising growth hormone is not the same thing as losing weight. A study showing that a peptide increases GH output tells you nothing about how many pounds a person will lose.

Stacking CJC-1295 with Ipamorelin or AOD-9604

Ipamorelin is a selective ghrelin receptor agonist that triggers GH release through a different pathway than GHRH analogs do. Many people combine the two, and searches for cjc 1295 ipamorelin for weight loss reflect how common that pairing has become. No controlled human trial has tested the combination for fat loss.

AOD-9604 is a fragment of human growth hormone that was studied specifically for fat metabolism. Discussion of aod-9604 dosage per day for weight loss usually cites 300 mcg once daily, yet a Phase IIb obesity trial reported that the peptide did not outperform placebo on weight loss.

Stacking multiplies unknowns. Each additional compound adds its own side effect profile, its own sourcing risk, and its own chance of interacting with prescription medications.

Side Effects, Legal Status, and Sourcing Risk

Reported side effects associated with GH-raising peptides include:

• Injection site pain, redness, or swelling
• Water retention and puffiness in the hands and feet
• Joint and muscle aches
• Numbness or tingling in the extremities
• Elevated fasting blood sugar and reduced insulin sensitivity
• Headache, flushing, and dizziness shortly after injection

Search interest in cjc 1295 dac for sale stays high, but buying a research chemical online carries genuine risk. Vials may be underdosed, mislabeled, or contaminated, and there is no pharmacy oversight or recall system behind them.

Peptides sold as research chemicals are not verified for purity, identity, or dose. A certificate of analysis from an unknown lab is marketing material, not proof.

What Actually Works for Weight Loss

Approved options with human trial data include GLP-1 and dual GLP-1/GIP medications, a structured calorie deficit, higher protein intake, and resistance training. Those approaches have measurable outcomes and known safety profiles.

Anyone considering a research peptide should talk with a healthcare professional first, especially if they have diabetes, thyroid disease, or a personal history of cancer. Blood sugar and IGF-1 monitoring matters whenever GH-related compounds are in the picture.

Weight loss is a slow, reversible process, and no injectable peptide replaces the fundamentals. Sustainable results come from habits you can keep, not from a vial with an unverified label.